INNOVENT BIO (01801) reaches a global exclusive license agreement with Roche for a new generation of DLL3 antibody-drug conjugates.

INNOVENT BIO (01801) announced that the company and its wholly-owned subsidiaries (including INNOVENT BIO Pharmaceuticals (Suzhou) Co., Ltd., Fortvita Biologics (Singapore) Pte. Ltd., and Frieda Biopharmaceutical Co., Ltd.) have reached a global exclusive collaboration and licensing agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively referred to as "Roche"). Under this agreement, the group has granted Roche the global exclusive rights to develop, manufacture, and commercialize IBI3009 (a new generation antibody-drug conjugate (ADC) targeting DLL3). IBI3009 has received clinical trial application (IND) approvals in Australia, China, and the United States, and the first patient dosing for the Phase I clinical study was completed in December 2024. This collaboration aims to provide a new treatment option for patients with advanced small cell lung cancer (SCLC). Under the agreement, the group and Roche will jointly be responsible for the early development of this ADC candidate drug, with Roche taking over the subsequent clinical development. The group will receive an upfront payment of $80 million, with potential milestone payments of up to $1 billion for development and commercialization milestones, as well as potential double-digit tiered royalties based on global annual net sales in the future.